| Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment. | Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment.
Tang P, Zheng G, Xu C, Yu N, Du J, Hu L, Zhou Z, Zheng Y., Free PMC Article | 08/15/2024 |
| NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells. | NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells.
Zhang Y, Yu H, He M, Liu W, Xiao S, Wang X, Huang P, Huang Q. | 07/28/2024 |
| Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR-486-5p/NEK2 axis. | Abnormal methylation mediated upregulation of LINC00857 boosts malignant progression of lung adenocarcinoma by modulating the miR-486-5p/NEK2 axis.
Fu H, Zhang M, Liu X, Yang Y, Xing Y., Free PMC Article | 06/11/2024 |
| NEK2 promotes the development of ovarian endometriosis and impairs decidualization by phosphorylating FOXO1. | NEK2 promotes the development of ovarian endometriosis and impairs decidualization by phosphorylating FOXO1.
Wang M, Sun F, Zhang S, Zhang X, Sun Y, Yu T, Li Y, Jiang A, Qiao P, Ren C, Yang T., Free PMC Article | 06/3/2024 |
| [Expression and clinical significance of NEK2 and EMT related molecules in oral squamous cell carcinoma]. | [Expression and clinical significance of NEK2 and EMT related molecules in oral squamous cell carcinoma].
Ye TT, Chen WH, Pei J, Jia YX, Wu HY. | 03/22/2024 |
| Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction. | Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction.
Kalkan BM, Ozcan SC, Cicek E, Gonen M, Acilan C., Free PMC Article | 03/18/2024 |
| Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers. | Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.
Jessen M, Gertzmann D, Liss F, Zenk F, Bähner L, Schöffler V, Schulte C, Maric HM, Ade CP, von Eyss B, Gaubatz S., Free PMC Article | 02/22/2024 |
| Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. | Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer.
Wu Z, Zheng J, Zhang H, Shen N, Luo X, Shen C, Song P, Zhang Y, Zhang M, Yang S, Guo G, Xue X, Zhang F, Feng S. | 03/11/2023 |
| NEK2 is associated with poor prognosis of clear cell renal cell carcinoma and promotes tumor cell growth and metastasis. | NEK2 is associated with poor prognosis of clear cell renal cell carcinoma and promotes tumor cell growth and metastasis.
Feng X, Jiang Y, Cui Y, Xu Y, Zhang Q, Xia Q, Chen Y. | 12/10/2022 |
| NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes. | NEK2 inactivates the Hippo pathway to advance the proliferation of cervical cancer cells by cooperating with STRIPAK complexes.
Zhang YR, Zheng PS. | 10/22/2022 |
| Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects. | Role of NIMA-related kinase 2 in lung cancer: Mechanisms and therapeutic prospects.
Shah D, Joshi M, Patel BM. | 09/24/2022 |
| NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143. | NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143.
Su W, Hu H, Ding Q, Wang M, Zhu Y, Zhang Z, Geng Z, Lin S, Zhou P., Free PMC Article | 06/25/2022 |
| NEK2 promotes the progression of liver cancer by resisting the cellular senescence.", trans "NEK2. | NEK2 promotes the progression of liver cancer by resisting the cellular senescence.
Lei Q, Xia J, Feng X, Guo J, Li G, Zhou W., Free PMC Article | 05/21/2022 |
| ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis. | ETV4 mediated lncRNA C2CD4D-AS1 overexpression contributes to the malignant phenotype of lung adenocarcinoma cells via miR-3681-3p/NEK2 axis.
Wang B, Cai Y, Li X, Kong Y, Fu H, Zhou J., Free PMC Article | 04/23/2022 |
| Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma. | Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma.
Feng X, Guo J, An G, Wu Y, Liu Z, Meng B, He N, Zhao X, Chen S, Zhu Y, Xia J, Li X, Yu Z, Li R, Ren G, Chen J, Wu M, He Y, Qiu L, Zhou J, Zhou W., Free PMC Article | 04/16/2022 |
| NEK2 enhances malignancies of glioblastoma via NIK/NF-kappaB pathway. | NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.
Xiang J, Alafate W, Wu W, Wang Y, Li X, Xie W, Bai X, Li R, Wang M, Wang J., Free PMC Article | 04/16/2022 |
| Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling. | Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.
Xing Z, Zhang M, Wang X, Liu J, Liu G, Feng K, Wang X. | 03/26/2022 |
| The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells. | The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
Rivera-Rivera Y, Marina M, Jusino S, Lee M, Velázquez JV, Chardón-Colón C, Vargas G, Padmanabhan J, Chellappan SP, Saavedra HI., Free PMC Article | 10/30/2021 |
| NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. | NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, Yadav DK, Bai X, Liang T., Free PMC Article | 08/7/2021 |
| High expression of NEK2 promotes gastric cancer progression via activating AKT signaling. | High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.
Wan H, Xu L, Zhang H, Wu F, Zeng W, Li T. | 08/7/2021 |
| High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR. | High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
Chen C, Peng S, Li P, Ma L, Gan X. | 06/26/2021 |
| Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells. | Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A, Padellan M, Marchenko N., Free PMC Article | 06/26/2021 |
| Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/beta-catenin signaling pathway in cervical cancer. | Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer.
Xu T, Zeng Y, Shi L, Yang Q, Chen Y, Wu G, Li G, Xu S., Free PMC Article | 06/5/2021 |
| High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms. | High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.
Motylewska E, Braun M, Stępień H., Free PMC Article | 06/5/2021 |
| Involvement of NEK2 and its interaction with NDC80 and CEP250 in hepatocellular carcinoma. | Involvement of NEK2 and its interaction with NDC80 and CEP250 in hepatocellular carcinoma.
Zeng L, Fan X, Wang X, Deng H, Zhang X, Zhang K, He S, Li N, Han Q, Liu Z., Free PMC Article | 05/15/2021 |